Lymphoma

Oncology
86
Pipeline Programs
30
Companies
50
Clinical Trials
3 recruiting
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
23
17
38
0
4
4
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1759%
Small Molecule
1034%
ADC
27%
+ 60 programs with unclassified modality

On Market (3)

Approved therapies currently available

U
APIXABANApproved
apixaban
Unknown Company
Factor Xa Inhibitor [EPC]oral2025
Roche
RITUXANApproved
rituximab
Roche
CD20-directed Cytolytic Antibody [EPC]intravenous1997
Pfizer
TORISELApproved
temsirolimus
Pfizer
intravenous2007

Competitive Landscape

36 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
5 programs
2
2
1
ApixabanPhase 31 trial
TemsirolimusPhase 31 trial
MaplirpaceptPhase 11 trial
maplirpaceptPhase 11 trial
Rituximab PfizerN/A1 trial
Active Trials
NCT06790420Completed1Est. Mar 2025
NCT03530683Terminated189Est. Jul 2024
NCT05567887Completed7Est. Oct 2024
+2 more trials
Roche
RocheSTAVANGER NORWAY, Norway
5 programs
1
3
1
1
RituximabPhase 3Monoclonal Antibody1 trial
Atezolizumab [TECENTRIQ]Phase 1/21 trial
BendamustinePhase 1/21 trial
ObinutuzumabPhase 1/2Monoclonal Antibody1 trial
AtezolizumabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT02220842Completed96Est. Jan 2020
NCT02729896Completed36Est. Oct 2019
NCT02257567Completed331Est. Oct 2021
+2 more trials
Takeda
TakedaTOKYO, Japan
2 programs
1
1
Brentuximab vedotinPhase 4ADC1 trial
TAK228Phase 1/21 trial
Active Trials
NCT02727777Terminated4Est. Jul 2018
NCT01909934Completed50Est. Aug 2024
GS
Gilead SciencesFOSTER CITY, CA
4 programs
1
2
1
immunoscintigraphyPhase 32 trials
LamivudinePhase 1/22 trials
LamivudinePhase 1/2
FludarabinePhase 11 trial
Active Trials
NCT04608487Active Not Recruiting18Est. Jun 2038
NCT01528865Withdrawn0
NCT00230477Completed19Est. Aug 2007
+2 more trials
Alliance Pharmaceuticals
15 programs
14
Bleomycin SulfatePhase 21 trial
Etoposide phosphatePhase 21 trial
carmustinePhase 21 trial
cladribinePhase 21 trial
dexamethasonePhase 22 trials
+10 more programs
Active Trials
NCT03224767Active Not Recruiting24Est. Aug 2028
NCT02157051Active Not Recruiting42Est. Sep 2026
NCT01664169Completed307Est. Aug 2018
+25 more trials
M&
Merck & Co.RAHWAY, NJ
5 programs
1
1
2
EntinostatPhase 2Small Molecule1 trial
PembrolizumabPhase 2Monoclonal Antibody1 trial
ZolinzaPhase 1/21 trial
PembrolizumabPhase 1Monoclonal Antibody1 trial
AprepitantN/A1 trial
Active Trials
NCT00651755Completed23Est. Sep 2011
NCT06475235Recruiting15Est. Jun 2027
NCT00787527Completed14Est. Dec 2012
+2 more trials
Biogen
5 programs
2
3
90-Y-ibritumomab tiuxetanPhase 21 trial
FludarabinePhase 21 trial
ZevalinPhase 21 trial
Y ZevalinPhase 1/22 trials
Zevalin RadioimmunotherapyPhase 1/21 trial
Active Trials
NCT00177554Completed60Est. May 2007
NCT01538472Completed40Est. Nov 2011
NCT00048737Completed70Est. Dec 2011
+3 more trials
Knight Therapeutics
Knight TherapeuticsQC - Montréal
5 programs
1
4
Xisomab 3G3Phase 21 trial
cytarabinePhase 21 trial
filgrastimPhase 21 trial
filgrastimPhase 21 trial
rituximabPhase 1/2Monoclonal Antibody1 trial
Active Trials
NCT00691652Terminated2Est. Apr 2009
NCT04465760Terminated9Est. Nov 2021
NCT00074191Completed1Est. Oct 2000
+2 more trials
AbbVie
AbbVieNORTH CHICAGO, IL
3 programs
1
1
VenetoclaxPhase 21 trial
duvelisibPhase 1Small Molecule1 trial
EpcoritamabN/AMonoclonal Antibody1 trial
Active Trials
NCT05692050No Longer Available
NCT02598570Completed7Est. Feb 2017
NCT06510309Recruiting33Est. Oct 2031
Astex Pharmaceuticals
3 programs
2
CytoxanPhase 21 trial
PentostatinPhase 2Small Molecule
multitargeted receptor tyrosine kinase inhibitor MP470N/A1 trial
Active Trials
NCT00504205TerminatedEst. Mar 2010
NCT00496873CompletedEst. Dec 2014
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
3 programs
1
1
1
cisplatinPhase 21 trial
bortezomibPhase 1/21 trial
TolbutamidePhase 11 trial
Active Trials
NCT01185548Terminated4Est. Dec 2010
NCT00290706Terminated32Est. Sep 2012
NCT00014209Completed77Est. Feb 2009
Bristol Myers Squibb
2 programs
1
NivolumabPhase 2Monoclonal Antibody1 trial
Digital Health CoachingN/A1 trial
Active Trials
NCT05064787Completed45Est. Feb 2024
NCT02038946Completed116Est. Dec 2020
Amgen
2 programs
1
1
CEEP regimenPhase 21 trial
IbrutinibPhase 1Small Molecule1 trial
Active Trials
NCT02269085Terminated8Est. May 2018
NCT00869284Completed45Est. Feb 2009
Novartis
NovartisBASEL, Switzerland
2 programs
1
1
CyclophosphamidePhase 21 trial
LBH589Phase 1/21 trial
Active Trials
NCT00621244Completed175Est. Dec 2009
NCT00101101Completed43Est. Jun 2021
Genentech
2 programs
2
AvastinPhase 21 trial
RituximabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT00081861Completed13Est. Sep 2007
NCT01939730Completed42Est. Sep 2013
Karyopharm Therapeutics
1 program
1
IbrutinibPhase 2Small Molecule
UP
1 program
1
Inotuzumab OzogamicinPhase 2ADC
Bayer
1 program
1
PentostatinPhase 2Small Molecule1 trial
Active Trials
NCT00453193Terminated26Est. Mar 2010
Sanofi
SanofiPARIS, France
1 program
1
SAR245409Phase 21 trial
Active Trials
NCT01403636Completed167Est. Sep 2014
Ipsen
IpsenChina - Tianjin
1 program
1
TazemetostatPhase 2Small Molecule1 trial
Active Trials
NCT06692452Suspended24Est. Oct 2032
TG Therapeutics
TG TherapeuticsNEW YORK, NY
1 program
1
UmbralisibPhase 2Small Molecule1 trial
Active Trials
NCT03919175TerminatedEst. May 2024
BioCryst Pharmaceuticals
2 programs
1
1
forodesine hydrochloridePhase 1/21 trial
forodesine hydrochloridePhase 11 trial
Active Trials
NCT00098332CompletedEst. Jul 2011
NCT00061880CompletedEst. Jan 2008
ModeX Therapeutics
1 program
1
MDX2003Phase 1/2
Opko Health
Opko HealthMIAMI, FL
1 program
1
MDX2003Phase 1/21 trial
Active Trials
NCT07249905RecruitingEst. Apr 2030
DS
Daiichi SankyoChina - Shanghai
1 program
1
RituximabPhase 1/2Monoclonal Antibody1 trial
Active Trials
NCT05683171Recruiting60Est. Sep 2027
Rigel Pharmaceuticals
Rigel PharmaceuticalsSOUTH SAN FRANCISCO, CA
1 program
1
fostamatinibPhase 1/2Small Molecule1 trial
Active Trials
NCT00446095CompletedEst. Oct 2010
Curis
CurisMA - Lexington
3 programs
3
CUDC-427Phase 11 trial
CUDC-907Phase 11 trial
fimepinostatPhase 1Small Molecule1 trial
Active Trials
NCT01908413TerminatedEst. Nov 2015
NCT02909777CompletedEst. Dec 2025
NCT01742988CompletedEst. Oct 2020
Cogent Biosciences
2 programs
2
ACTR087Phase 11 trial
ACTR707Phase 11 trial
Active Trials
NCT02776813Completed34Est. Feb 2020
NCT03189836Terminated26Est. Sep 2020
Treeline Biosciences
Treeline BiosciencesCA - San Diego
2 programs
2
TLN-121Phase 11 trial
TLN-254Phase 11 trial
Active Trials
NCT07082803RecruitingEst. Nov 2030
NCT06733441RecruitingEst. Nov 2028
Astellas
AstellasChina - Shenyang
1 program
1
ASP4132Phase 11 trial
Active Trials
NCT02383368Completed39Est. Apr 2018

+6 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
TakedaBrentuximab vedotin
Gilead SciencesLamivudine
Alliance Pharmaceuticalsrituximab
Alliance Pharmaceuticalsrituximab
PfizerApixaban
RocheRituximab
Alliance Pharmaceuticalsrituximab
PfizerTemsirolimus
Alliance Pharmaceuticalsrituximab
Alliance Pharmaceuticalsfilgrastim
Gilead Sciencesimmunoscintigraphy
Alliance Pharmaceuticalsdexamethasone
Alliance Pharmaceuticalslaboratory biomarker analysis
Gilead Sciencesimmunoscintigraphy
AbbVieVenetoclax

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 6,545 patients across 50 trials

NCT01909934TakedaBrentuximab vedotin

Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Start: Jan 2014Est. completion: Aug 202450 patients
Phase 4Completed
NCT00230477Gilead SciencesLamivudine

Hepsera Versus Hepsera Plus Lamivudine for Treatment of Chronic Hepatitis B in Patients With Normal ALT

Start: Apr 2003Est. completion: Aug 200719 patients
Phase 4Completed
NCT05976763Alliance Pharmaceuticalsrituximab

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

Start: Oct 2023Est. completion: Aug 2038421 patients
Phase 3Recruiting
NCT03150693Alliance Pharmaceuticalsrituximab

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Start: Sep 2017Est. completion: Aug 2027310 patients
Phase 3Suspended
NCT02369653PfizerApixaban

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

Start: Oct 2015Est. completion: Jul 2021512 patients
Phase 3Completed
NCT01889069RocheRituximab

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)

Start: Jul 2013Est. completion: May 2019159 patients
Phase 3Completed
NCT00513747Alliance Pharmaceuticalsrituximab

Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia

Start: Jan 2008Est. completion: Jun 201684 patients
Phase 3Terminated
NCT00117598PfizerTemsirolimus

Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)

Start: May 2005Est. completion: Jan 2011169 patients
Phase 3Completed
NCT00118209Alliance Pharmaceuticalsrituximab

Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Start: May 2005Est. completion: Nov 2021524 patients
Phase 3Completed
NCT00014534Alliance Pharmaceuticalsfilgrastim

Combination Chemotherapy in Treating Patients With Bladder Cancer

Start: Mar 2004Est. completion: Apr 200942 patients
Phase 3Completed
NCT00003337Gilead Sciencesimmunoscintigraphy

Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma

Start: Mar 1997100 patients
Phase 3Unknown
NCT06212336Alliance Pharmaceuticalsdexamethasone

ISTH/ANRS 0409s INTEGRATE Lassa Fever Study

Start: May 2025Est. completion: Jun 20271,755 patients
Phase 2/3Recruiting
NCT01189253Alliance Pharmaceuticalslaboratory biomarker analysis

Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma

Start: May 2011Est. completion: Jun 2015133 patients
Phase 2/3Terminated
NCT00003338Gilead Sciencesimmunoscintigraphy

Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma

Start: Mar 199760 patients
Phase 2/3Unknown
NCT06510309AbbVieVenetoclax

Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma

Start: Feb 2026Est. completion: Oct 203133 patients
Phase 2Recruiting
NCT06692452IpsenTazemetostat

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Start: Dec 2024Est. completion: Oct 203224 patients
Phase 2Suspended
NCT05303792Alliance Pharmaceuticalsrituximab

Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma

Start: Jun 2023Est. completion: May 202868 patients
Phase 2Active Not Recruiting
NCT04465760Knight TherapeuticsXisomab 3G3

Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy

Start: Feb 2021Est. completion: Nov 20219 patients
Phase 2Terminated
NCT03919175TG TherapeuticsUmbralisib

Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma

Start: Sep 2019Est. completion: May 2024
Phase 2Terminated
NCT03224767Alliance Pharmaceuticalslaboratory biomarker analysis

Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

Start: Jan 2018Est. completion: Aug 202824 patients
Phase 2Active Not Recruiting
NCT03316573Merck & Co.Pembrolizumab

Pembrolizumab in Neoplasms or Lymphomas

Start: Dec 2017Est. completion: Mar 202618 patients
Phase 2Suspended
NCT03179930Merck & Co.Entinostat

Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas

Start: Jun 2017Est. completion: Jun 202647 patients
Phase 2Active Not Recruiting
NCT02038946Bristol Myers SquibbNivolumab

Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)

Start: Mar 2014Est. completion: Dec 2020116 patients
Phase 2Completed
NCT01511562Alliance Pharmaceuticalscarmustine

Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma

Start: Sep 2012Est. completion: May 2027113 patients
Phase 2Active Not Recruiting
NCT01486277Johnson & JohnsonJNJ-26481585

A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma

Start: Nov 2011Est. completion: Jul 201626 patients
Phase 2Completed
NCT01403636SanofiSAR245409

A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia

Start: Oct 2011Est. completion: Sep 2014167 patients
Phase 2Completed
NCT01190449Alliance Pharmaceuticalsofatumumab

Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Start: Aug 2011Est. completion: Oct 202051 patients
Phase 2Completed
NCT01132807Alliance PharmaceuticalsBleomycin Sulfate

Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

Start: May 2010Est. completion: Jan 2018164 patients
Phase 2Completed
NCT01027000Alliance Pharmaceuticalsrituximab

Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Start: Feb 2010Est. completion: Apr 202368 patients
Phase 2Completed
NCT00460109Alliance Pharmaceuticalsrituximab

Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma

Start: Apr 2008Est. completion: Mar 201124 patients
Phase 2Completed
NCT00553501Alliance Pharmaceuticalsrituximab

Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma

Start: Mar 2008Est. completion: Jul 201460 patients
Phase 2Completed
NCT00073983Alliance Pharmaceuticalsfilgrastim

Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma

Start: Oct 2006Est. completion: Dec 201054 patients
Phase 2Completed
NCT00310037Alliance Pharmaceuticalsrituximab

Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma

Start: Jun 2006Est. completion: Jun 2022151 patients
Phase 2Completed
NCT00493454BiogenZevalin

Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas

Start: Apr 2006Est. completion: Mar 20116 patients
Phase 2Terminated
NCT00238238Alliance Pharmaceuticalsrituximab

Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab

Start: Mar 2006Est. completion: Aug 201597 patients
Phase 2Completed
NCT00301821Alliance Pharmaceuticalsepratuzumab

Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Start: Jan 2006Est. completion: Apr 2015107 patients
Phase 2Completed
NCT00304083Alliance Pharmaceuticalsfilgrastim

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors

Start: Dec 2005Est. completion: Jun 201448 patients
Phase 2Completed
NCT00117975Alliance Pharmaceuticalsgaliximab

Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

Start: Jun 2005Est. completion: Aug 201362 patients
Phase 2Completed
NCT00496873Astex PharmaceuticalsCytoxan

Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan

Start: Jun 2005Est. completion: Dec 2014
Phase 2Completed
NCT00238433Knight Therapeuticsfilgrastim

Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma

Start: Mar 2005Est. completion: Dec 201637 patients
Phase 2Completed
NCT00098774Alliance Pharmaceuticalsrituximab

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma

Start: Oct 2004Est. completion: Sep 201447 patients
Phase 2Completed
NCT00453193BayerPentostatin

Alemtuzumab and Pentostatin In T-cell Neoplasms

Start: Sep 2004Est. completion: Mar 201026 patients
Phase 2Terminated
NCT00077311Alliance Pharmaceuticalsfilgrastim

Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Start: Aug 2004Est. completion: Apr 2009160 patients
Phase 2Completed
NCT00101101NovartisCyclophosphamide

Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma

Start: Jul 2004Est. completion: Jun 202143 patients
Phase 2Completed
NCT00290511BiogenFludarabine

Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma

Start: Jun 2004Est. completion: Feb 202149 patients
Phase 2Completed
NCT00062114Alliance Pharmaceuticalsrituximab

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

Start: Apr 2004Est. completion: Apr 200784 patients
Phase 2Completed
NCT00081861GenentechAvastin

Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma

Start: Mar 2004Est. completion: Sep 200713 patients
Phase 2Completed
NCT00070135Alliance Pharmaceuticalsfilgrastim

Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission

Start: Jan 2004Est. completion: Jun 2016121 patients
Phase 2Completed
NCT00177554BiogenY Zevalin

Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma

Start: Nov 2003Est. completion: May 200760 patients
Phase 2Completed
NCT00053027Alliance Pharmaceuticalsrituximab

Rituximab and Cladribine in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma

Start: Feb 2003Est. completion: Nov 200930 patients
Phase 2Completed

Related Jobs in Oncology

Cell Therapy Account Manager（北陸）

Gilead Sciences
Japan - Tokyo
Just now

Leo Cancer Care: Senior In-House Counsel/General Counsel

Leo Cancer Care
Middleton, Wisconsin
1h ago

Summer Intern - Computational Chemistry & Artificial Intelligence

Arvinas
Remote
3h ago

Executive Director, I.T.- Head of Security Architecture, Engineering, and Delivery

Gilead Sciences
United States - California - Foster City
17h ago
$281K - $364K/yr

Sr Research Associate, Analytical Operations

Gilead Sciences
United States - California - Oceanside
17h ago
$86K - $112K/yr

Associate Director, Insights & Analytics Platform Technology Lead

Gilead Sciences
United States - California - Foster City
17h ago
$196K - $253K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs — potential near-term approvals
3 actively recruiting trials targeting 6,545 patients
30 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)